Gd-IgA1 (galactose-deficient IgA1)

Class

TRAP degrader (Biohaven's targeted extracellular protein-degradation platform)

Pathway

IgA nephropathy pathogenic autoantibody clearance

Immunoglobulin A nephropathy (IgAN) is a kidney disease in which a form of antibody called galactose-deficient IgA1 (Gd-IgA1) plays a central pathogenic role. Normal IgA1 molecules carry sugar chains (O-glycans) in a hinge region; in IgAN, a subset of circulating IgA1 is under-galactosylated. This altered sugar pattern is recognized as foreign by other antibodies, which bind to it and form immune complexes. These complexes lodge in the glomerular mesangium, the supportive tissue at the kidney's filtering units, where they trigger local inflammation, complement activation, and progressive scarring that can erode kidney function over time. Because Gd-IgA1 sits upstream of this entire cascade, removing it from circulation before it can form deposits is an attractive therapeutic strategy, distinct from approaches that instead target the immune cells producing the antibody or the downstream inflammatory signals. The TRAP (targeted extracellular protein degradation) approach described here works by engaging circulating Gd-IgA1 and redirecting it toward cellular clearance pathways, effectively accelerating its removal rather than blocking its formation. This class of mechanism is relevant broadly to diseases driven by a defined, quantifiable circulating pathogenic protein, where reducing its abundance is expected to lessen tissue injury.